PredicineBEACON™ platform offers next-generation, tissue-agnostic MRD detection, leveraging blood, urine- and/or tissue-based comprehensive genomic profiling solutions in solid tumors including bladder, prostate, and renal tumors. MRD detection with PredicineBEACON™ is not limited by baseline tissue sample availability. If available, baseline samples can be assessed using patient’s blood, urine or tissue. Monitoring recurrence or progression of cancer can be achieved with a simple blood draw or urine sample. Monitoring intervals can be customized according to risk or medical necessity.